

BUSINESS NEWS – 23rd November 2021

Mirati Therapeutics and Verastem Oncology Partner to Evaluate Adagrasib in Combination with VS-6766 in KRASG12C-Mutant NSCLC

"We are pleased to collaborate with Verastem Oncology on this clinical study of VS-6766 and adagrasib. We believe the data from this trial will help to better understand how these agents, when combined, could help improve patient outcomes," said James Christensen, Ph.D., chief scientific officer, Mirati Therapeutics, Inc. "This clinical collaboration is an example of how Mirati is aggressively advancing the study of adagrasib both as a monotherapy and in rational combinations as part of its expanding development portfolio to benefit people living with difficult-to-treat cancers."

Tempus Signs Strategic Collaboration Agreement With AstraZeneca to Advance Oncology Therapeutics

"Artificial intelligence has the potential to advance precision medicine in ways that seemed unimaginable just a few short years ago," said Eric Lefkowsky, Founder and CEO of Tempus. "We look forward to working with AstraZeneca to apply AI-enabled solutions to advance its robust therapeutic pipeline in an effort to help patients live longer and healthier lives."

Gilead Exercises Options to Three Arcus Biosciences Clinical-Stage Programs and Adds Research Collaboration

"Gilead is pursuing some of the most promising mechanisms of action in oncology today, with the aim of achieving better treatment outcomes for more patients," said Daniel O'Day, Chairman and Chief Executive Officer, Gilead Sciences. "The addition of three mid- to late-stage clinical programs into our oncology pipeline significantly expands the number of transformational medicines we can potentially deliver to people with cancer, while also enabling our pursuit of novel combinations."

Phosplatin Therapeutics Collaborates with the NCI For Ph 2 Proof of Concept Study of PT-112 in Thymoma and Thymic Carcinoma

"Thymoma and thymic carcinoma are rare forms of cancer for which there is currently no FDA approved treatment. There remains a pressing need for novel therapies for relapsed and refractory TETs – induction of immunogenic cell death is an approach of great interest for this population with no approved immunotherapy treatment," said Arun Rajan, MD, Senior Clinician in the Thoracic and GI Malignancies Branch at the National Cancer Institute. "This clinical trial will evaluate PT-112 as a potential treatment option for our patients with TETs, and we hope to better understand PT-112's therapeutic potential through this collaborative research program."

Celcuity Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Provide Ibrance for Planned Ph 3 Clinical Trial

"We are excited that Pfizer is providing palbociclib for this important Phase 3 clinical trial," said Brian Sullivan, Chief Executive Officer and co-founder of Celcuity. "Our goal is to address the

significant unmet need for new therapeutic options for patients who progressed on their first line of treatment for ER+/HER2- advanced breast cancer."

SOTIO Expands its Antibody-Drug Conjugate Pipeline with Exclusive Collaboration and License Agreement with LegoChem Biosciences

"At SOTIO we are building an innovative pipeline of ADC programs and plan IND filing for our lead program SOT102 by the end of 2021. The licensing agreement with our new, experienced partner LegoChem allows us to broaden our oncology pipeline with additional programs and solid tumor targets. We are looking forward to using the potential of LegoChem's ADC technology platform and to develop innovative ADCs for patients in need," said Radek Spisek, M.D., Ph.D., chief executive officer of SOTIO.